Introduction
Hbrinogt!n is a lridoillainal di!>ulfidc linked protein comprised of two ~ymmetl;cal halves, each composed fif three polypeptide chain:-termed /\0:, B~, and y (1-3), Human lihri llogcll can be separated by ion exchangc chromalngraphy into lWO major fract ion s, fibrinogen 1 ("peak I fi brinogen") 311d fi brinogen 2 ("peak 2 fi hrinogen") (4, 5) , The twu fi brinogens differ from ~ach olher with respect 10 th~ composition of their 'Y chains. Fibrjnogen I contains two "' fA ch<1ins \-' , ·hich are coropri'led of 411 amino acids . Hetcrou inlt::[;c fibrinogen 2 molecllles each contain one "/,I, ami one ,,/ ' chai n (6 , 7) . The variant y ' chain is longer (427 residue s), and has a more anioni c, c-<' u boxyl H~lm il1al sequence than the "fA ch"in beyond position 4()X (Ii). Factor Xlii has been shown 10 bind 10 the )-chains ill fibrinogen 2 (9) and thrombin has also been shown to biod to Ihe Slime anionic -y'extcnsion of fi brin 2 ( III), Follow ing thc rapi d thrombin-mediated cleavage offihrinopcplidl": A (11 -15) [l.lld s]m·ver c1 ea\'age of fi brinopeptidc B (\ 6-1R), fibrll.l as~embly commences with formatiolJ or doubl{! stranded twisting fi.brils in which fi brin molecu les arc "'lTanged in a Maggered overlapping manner (19) (20) (21) (22) (23) (24) (25) (26) . Subscquently, laleral fibril assoc i ation~ oct.:ur, resulting i .n thick fibcr~ (22, 26-2H) . Concom itant witll cOllverting fibrin ogen to fibrin, thrombin activates factor XTTlto facto]' XIIIa. In the presence of fXllla and Cal+, fibri n undcrgoci intermolecular covalent crosslinking by l(lIma tion of E-amino(,,:,-glut.. 1myl) lysi ne isopeptide bonds (29, 30) . Crossli nking of ' Y chains within fi brils OCCllrs belween properly aligned chain s at ly sine 406 of one "I chain, and a glutamim: at IX)sitioll 398 or 399 of another to form ' Y djmcr~ (31 ,32) . Intermolecular cro sshnk ing Ix:lw~t:1l u chaills creates oiigomers and larger a: chain polymer'i and Ol'curs more slowly than "I dimeriz-ation (32, 33) . Gamma trimer' > and "I tetramcrs fonn after more prOlonged illt.:ubalion (19) . l-'aclor XlIla can also cro)sl ink frhrinogen, alheit at a somewhat slower rate (34. 35) . Crosslinked fibrinog en for ms a transl ucent. non-syncl'i7.ing gel, that is [lssociatcd with "I di mer for mation (34, 35) .
Plasma factor XfII (protransglu taminasc, is a noncovalent tct ralilt ric protein complex composed of IWO pairs or subun it chains termed "A"
ami "8", rcspc"Ctive1y (36~3 S). Thrombin cleavage at position 37 of the A ~ubll nit~ (3 9-4 1) leads to format ion of Ihe active enzyme. factor XlTJa (transgllllaminase), which itself reqLlires Ca2~ fo r dissociation or the act ivated sublmits { A 2:~) from the B su bunit~ and ror full expression of ils cJWlylie acti vity . Act ivation of rxm an(j Ihe activity of lllromb Haemost 2001: S6: 122I-S fXlTIa is promoted in the presence of fibrinogen 1:45-51) amI perhaps eveUlllore spe,cilically, by fibrin (47) (48) (49) (50) (51) (52) (53) (54) , Inhibition offibrinpolymer~ izatioll with the peptide GPRP, eliminates the enhancing effect of fibrin on fXlII activation (49, 52, 55) Hllman fibrinogen was isolated from p{)Oleci citrated plilsma by glycine precipitation (5S), and further purified as previously described (59) . [ 2 m1rino-gen was sllbfract\Onated into fibrinugcn I (y .. -"YA) and fibrinogen 2 (y\-,{') by chwmalOgraphy 011 DE-52 (91. Fibrinogen 1 is factor XIII frce, sincc all of tbe contmllinaLi[lg plasma ['Xlii eluLes with fibrinogen 2 (9). The fibrinogen 2 used in tllCse studies contained Icss than 5 Loev,"y units of lXlll actiYity per milligram of total protein. Soluble fihrin monomer Vias prepmed by the method of Rei itsel' et ~ll. [OO}. ri hl'inogen and ~olllble fibrin concentrations Wl'rc ddermined spectrophotomelrinilly at 280 nm using an absorhanee coefficient V\:~;~,J of lSI (61) Factor XIII 'was purified from pooled 11UnlUl1 pla~mu (62) and assayed 011 fXIJJ free fibrin substrates (prepared from fibrinogen 1) in tI1C prese-nee of 10 mM CaCl:, as lhrombin-activated fXIIIa as described by Locwy el aL (63) , Factor XIII concenlratiom were determined spectmpl10tometrically at 280 11m lIsillg an cxtinction coefficient (A](~", ) of 1.1.N (l6)_ The specific erosslinking activitie~ or the (hromhin-activated [XIII preparations ,,'cre bet\'ieen 2100 and 2300 Loewy u/mg_ TIle [1oobl human pbma (fibrinogen level, 2_S3 Illg/llll) used in thesc studies contained 105 Loe .... ) u/mll'actor XIII ~li:tivity and single donor plaslllas range from SS to 120 u/ml. PlII-i fieL! I'aclor XIII zymogen f loaded at 2D Ilgiband/lane) was re~olved into tvm bands by non-reducing SUS-PAGE (M), the A sulmnit 01 '75 
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Typicill crm,linking reaction mixtures contained fibrillugell I U lll!:!l, I ' (19, 66) . Factor XIII or XIlJa activity was also determined lIsing N,N'-dime[hlj. casein and l~C-cadaverine as sub~traLcs as described by Lon.nd et al. 
Results
The time course of plasma facto!.' Xlll-medialed crosslil~king (li fibrinogen is presented in Fig. 1 . Gamma 
rig,2 Cnlcium iun sensitivity of fibrinogen crosslinking by plasm~ fXIII_ Fibrinogen 1 (\ mgfmll and fXIIl (I UU Loewy ufml) were incubated as described til i\btcrials and Mcthoos with the indicated concenlrations o1CaC1 2 , Rcacliulls Ilerc terminated hy adding gel sample bllffer eontainlllg 1 t)'~ ~-meITaploelha [[01. allLithe products were separated by SUS-PAGE t'ibrinogell gels as early as 24 h into the incubalion period and tbeir conCentrations incrca~ed \vilb increasing times of incllbation (data not \10WI1J. Crosslinking and gel formation was nor due to contaminating lhrombin activating the proteills since lleither fibrinupeptidc A or B nor :he ["Xlii acriv<liion peptide could be detected in the rcaction mixtures The amount of fibrinogen incorporated into insoluble gels was direclly proporlionalto the amount of tXllI prescnt in thc reaction mix ~ ture (Tal)le I). CalciL1m ions arc absolutely requircd for fXIIl-ll1cdiatcd crosslinking of fihrinogen, since in the abscncc of calcium no crosslinking \\i<1S detected even aftcr 24 11 (Fig, 2) , COl1eenlrations of Ca> as low as 50 ).1M were sufficient 1.0 produce an easily measurable degree of "I chain crosslin king and the amount of "I dimer formation increased with increasing Ca> cOllcenlrations. Alpha polymcrs wcrc detcctcd in tbe reaction mixtures at Ca 2t concentrations above I mM. Optimal fibrinogen crosslinking \l,'as achieved at 24 h at 5 111M Ca 2t or higher. 'I'hiol reagents, though not required for plasma IXlIT-medlated fihrinogcn gelation, ncvertbeless increased the amount of fihrinogen rendered insoluble (Table 2) (Fig. 3) 
The rate of crosslin king catalyzed by plasma lXTlT and lhrombill-.\([inlted tXlIla are compared in Fig, 4 The fact that fibl'inogen 2 binds plasma factor XlII B subunits (lJj SLl£"2ested that non-covalent assoCIation of H and A snhllnits on fibrino-'Tt';l~ 2 might rL111ction to supprcss fXIII crosslinking activity. Indeed. ~\'hel1 fibrinogen 2 \vas incubated with plasma fXl11 the lag time of the (['osslin~ing reaction was nearly twice as long as Lhat observed \vith fibrinogen 1 and the maximum rate of fibrinogen crosslinking was uecreased 3.5-fold (Fig. 5) . This suggesLs lhat the complex formed tll.'twecn tibrinoge1l2 and plasma 1'X1ll eCfecLively slowed the development of crmslinking activity of the catalytic Al subunits by slmving their release from the complex.
The relative rate of crosslinking by fXIII and fXlIla ",las very differtilt with :.i.N'-dimethylcasein as a substrale cOlI\pared with fibrinogen or fibrin (Fig. 6) . At an activity level of 100 Loe\l,ly uimL thrombinadil'ateJ IXII1a incorporated 14C-cadaverinc into casein at least]O rold mort: rapidly than did the factor XUl zymogen, v,rhich had very little adi',"1ty. These findings suggcst that the robust transglutaminase activity displaycd by of factor XIII lS specific for fibrinogen or fibrin as sublrates since it occurs vcry poorly with a nOll-physiological substrate like casein.
il seemed possible that a small amount of facLor XIII had become activated during the purification process I~alheit undetectable by SDS-PAGE:!. To assess this possibility, fibrinogen crosslinking with pooled hllman plasilla as the IXIII source was compared with the pllriJ"ied plasma lXIII (Fig. 7) . The rcaction mixtures containing the plasma as the source of t'XIII formed insoluble crosslinked fiblinogen at a faster rate and to a larger extent than did samples containing an equivalent p{1tential activity of purified rxm. The effect was more marked in Ibe 
Discussion
These present studies show that fibrinogen can be cnlsslillked and rendered insoluble during a Ca 2 + dependent, thiol-enhanced reaction catalyzed by plasllla factor XIII. In our hands, an easily appreciable level o/' crosslinking can he achieved at Ca> at cOllccntrmiuns ahove SO ~M, and that the effect is augmented at OTT concentralions above 2.5 ",dvl. The rcsults show that: I, cellular and plasma I'actor XIII both
itself does nol accou nt ror the observed crosslin king activ ity of lXIII, since plasm:l could more than adequately replat:i: puri fied fXlII :IS a soun:c of activity; 5, when fi brinogen or fi brin is crossli nked by plusm:t fXIII there is always an inil ial lag in rhe developmenl of the max imal crosslinkin£ ratc: 6, [XIII c("()sslinking activity is spccifi<.: for fibrinogen (or fi bri n) as suhslrale(s) inasmuch as only very low lran5glutamill:l, <. ;e activi ty was c!eteclcd when cadaverine and ~,N' -dilli e t h yka~dn W~~fC employed as substrates in the reaction, These data suggest th,lt dllri ng the hlg phase of the reaction fibrinogen suhstrate mol ecules bind D.l or Ilcar the act ive si L e or· lxm causing a conformali onal changc Ihal renders the "zymogen" catalytically active and that may also lead to dissociation of A and B subunits, Fibrinogen 2 slows the rate of crosslinking by binding the B subunits of the zymogen and re!-,training the diffusion of the catalytic A 'iubunits, shown that "platelet" lXIII could be activated intracellularly in a thrombi n-independelH manner. All of these act ivation phenomena req uired Ca:!t, occUlred after secretion and plalelet <lg..l!regation wert: cumpleted. and resu lted in UIC crosslillking of cel lular proteins. In tile l<tllcr two studies (69 ,70) the authors postulated that the activation process might require the inl.eraction of "platel et" fXfH \vith some othcr cellul ar proTein, The pre,enl I' esults suggesl Ihe platelet component that cou ld serve aii , 'mhstrate for uncleaved fXITI, may be fibrinogen itsdf. A COIll' ormutionul change in factor XIII induced by fihri n(ogen) in the presence of Cu:!t may be more important in the non-catalytic activation at' fX 11l than is removal of the activation pepLide it self, since X-ray cl'Y~taliograph i c swJies llll lhrombin-cleav ed rel:umbinant cellular tXIU ( .~) de.monSlraLed 110 large conf0l111ational changes in the molecu le (7 1).
The pathophysiological ro le pJil)'ed by nnactivllted factor XII I in the circulation is unclcar. but sevcral considc-rations suggesr that it i~ a read ily available source of fibrin cros!)li nking activ it)' during early phases of fi bl;n elOi formation. Plasma factor XlU is cleaved rel:ll ively slowly by thrombin compared to [hrombill cleavage of fi brinogell (47 , 72) , <Ind tlUl\ > crosslink.i ng aClivity due tu fXllla format ion would he min imally available during early phases of throlilbill-rIlcuialtd d ot fl)l1llClI i(\n, Moreover, si n<.:e fib rin is a mllch better substrate for crosslinking than is librinogen 1)4, 35, L his study ), lhe cro~s lill king pOlemi (li of dot~i ncorporatcd fX TIJ vlould he selective for fihrin ()Ver fi brinogen, Rc(;c, lIt ~tudie-s of Ancrod infLlsiolls in lmtnnns (Tl) ~I rong l ) ' supports rhe idea that plasma fXIII is a [X)tent source of cros.,l inking activity, Allcrod is a purified snake vGl10m GnzymG from the Malnyrtll pit viper Ca{{osel£lsnla rhot/ostoliUl that clots ribt'inogen by sckctively cleavi ng Jibrinopeptide A, Lnlike thrombin, it has no capacity LO cleave factor XlII (74), In thei.r study, DcmpOe el al. (3) llleasun:u the cJTccls of Ancl'lJ(1 ad minis tration to normal volunteers, and early in the c our~e of the infus ion Ihey found sohlhle crosslink e( l fi brin c-omplexe$. followed somewhat later by the appearance of a cm~s li n ked fi blin ctcg rada~io ll product, D dimer. Since there-was 00 evidence that thrombin genera· lion had oc(;urred. these crosslinked products must havc arisen through tht constilllli vc crosslinking activity of fac tor XIII acting on Ancrudinduced fibrin.
Th~re are several observatiolls that probably rC\rl'allhe footprinr of fXlII activity in plasma, r\ormal pla<;ma fibrinogen contains readil y measl1I'ablc iU 1l0unts of intermole.cularly crossli nl-.;eLl "I dimcl's and intramolcc ulmly cl'Osslinl-.;ed Aa-"I helcriXl imc rs (75) , The relative con. tribution by lXIII versus a tis<;ne transglut1lminuse in for ming th~t crosslinked fihrinogens cannul be lJj st ingu i~hcd , but nc\,ert hek'ss raise, suspicion that fXllJ i<; invul ved ill their fonllutioJl. l't?-aliliplasmin i; anolher possible 'iubstrate-for the intri nsic activity of ciKulalillg !"XIII It has heen known fo r some rime that [here i~ .1 potent plasmin iohibi: tory acti vity bound to fi bri nogen (76) . Although Ihe speci fic C'lItity:o fi brinogen accounti ng for thal acti vity was not identified , we iflfer from more recent studies (see belmv ) that the inhibitory ,«,'Iivity \\t,L): aUri. bUlable to the presence of a 2-antipla~min ~'ovalcntl y crossUnktrll o fibrinogen, Recently, Siebenli sl Cl aI, (77) demon strated lhe pr('~l:I1(e of cov alently bound li 2 -antipbstnill in lIo]']nal f'ibrinogell as ' 11-' 1:11 as in ~ dysfibrinogenem;a known as fibrinoge.n Cedar Rapids (,' yR275C), We specnl8te that the Ct 2 -antiplasmin had occome: im'orporated i11\O Cibrino. gen through the action or fXTfT, ill it lllanner th;t!. is entirely anali)g()li~, 1 0 The crosslinki ng reaction that was demonstrated between fibrin llgcnand tXllIa by Tchinose and Aoki (7S), Fllnher, th e co nst itutive cro;;\!inlin2 activity of fXUI might conce ivably also account for some or all llf l~~ cMsJin.k.ed tihrinogen products that arc founu ill bnscmcllI mCmbraTli\ (79) and ill atherosclerotic plaques (80). [0 ,u.lditiun, the imrillsic aeTjyilr of IX1l1 could measllrably contribute to formation uf the cro'!lsl inked fibrin(ogcn) ' Y chains that occur in pathologkaJ "cryofibrinogen" complexes (81,82).
Familial MedilcrraLlean Fever (FMf) is lin herediTary disease in which cryofiblinogenemia is known to occur (83.84) and is a~sociated with increased fib rill{ogen) cros~lj nkin g (84) , The genc respow, :jblc ~or ca u~i n g the disease has been cloned (HS ), but th e p,lt hogcne~i~ or (he disorder remains llIKcl1ain, I:MP is characteri zed by illte,rmittcll l febrile episodes, abdominal pain, pleurisy, and arthritis (Rfi), A substanlial pro· portion of individuals with untreated disease eventually deveiop amyloidosis and renal failure (83) , Although cryotihrinogencmia occur, commonly in FMF subjects. and is usually regarded as a marklA for a hypercl)agulablc or thrombotic state (81, 82), F~1 f pati e nt~ do not manifest a thrombophilic phenotype (83), The <' : l'yufibrilloge.n precip:-tarcs found in FMF contain high lc:wls or "'Tos~li nkcd fibrinogen ' Y :Ilxl (A) (l chains (84) . and it seems possible that .\lome of the ciinic<ll m;m:-fcstatiolls of FMF could be rdated to enhanced IXIII activity ltadingl(l fo rmalion of increased level s of circulating crossl inked fi b ri n~}ten.
Moaddcl I:t al. (87) recently cuncluded from the re<;ulls or sedimer.-fation equi li brium experiments OIl plasma fXlll-libri nogen !nixmrcs containi ng I mtvI CaCI]" thal high affiill ty non -covalent co mplex~s had funned between tXIII and either fibrinogen I ("I", l'A) Of fih!'i nogcn ~ ("t;\ , "I')' In the case o/" C lbrinogen I. the apparent a s~ociati on (Olbtatll (K) \liaS 1,3 X lOS , and \vas caicium-deperlc\el1t b~(.: all se no COlllp lexo formed in the presence or EDTt\. , The apparell ( Ku for the fibl'iilogen ~ ("I A' -y ' )-factnr XIII "complex" Vias nearly thirty-fold higher. ~,6 X II)~ These Kit values seem quite hi gh in their own light for a pre~urtl cd non· covale nt molecular interaction, especially considerin g an earli er n:port that only -(-containing fibrino gen 1 hud any dClllonqrahk I)inciing affinity for facto r XII[ (9). Their interpretati on thaI nOIl-covabn (omplexes had fonned depended upon the assump tion that unactivo.lt:u faclOr XIII could not promote cru~sliJ1king of ti hlinogcn in the prc,\cna-0 1 C t 1 .. , which we show here 10 he incorrect. 'l1ll1s, conclusions C01lCt11l-jng non-covalent complex fonnalion belween [XIII <IIlU IIbrino,:!en will have to be validated hy a different set of experiments, sinc\! it s~t."n~ certain thm factor xm-cl1)sslitlkcd tlbrinogen m o l ec u l~ had bt\'~ produced during the course of L hcil ' ;la~elillC eJlzymatic pulcntial of [XIII. Recent reports indicaLe thaL thiol levels ill plasma can be greaLet-than 3m 11M (88). It therefore seems ler" likely thM plasma contallls "inhibitory clements" that supprcss or 1l1odulate the illtrinsic fXllI activity. One ~IICh factor \Vllllid he rihrinorell2 itself, given that the "/' chain-containing, tXlIf-binding form of fibrinogen becomes crosslinked hy fXU] at a much 100ver rate than Ilbrinogcll 1. The high levels of B subunits that arc present in plasma l11i£ht provide a second suppressive elemenl, since B subunits are kn;wn to prevelll lhruillbin-ilidependelit activation of "platelet" factor XlIl (68} and their presence results in a lag in the onsct of crosslinking by plasma tXIII. Another impo11ant down-regulating effect would be the fact that fihl'in is a better substrate ror fXm crosslinking tban is fibnnogen (34, 35 , this study) and therefore the rate at which (rosslin~il1g takes place in the normal fibrinogen-containing plasma enl'ironment is typically much lower than it \vould be if fibrin were present.
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